Ang-2 – Angiopoietin-2 predicts the efficacy of an angiogenesis inhibitor in colorectal cancer therapy

The invention provides a novel predictive biomarker to help identify the patient population with the most
favorable clinical outcome to angiogenesis-targeted treatment in mCRC patients. Experiments revealed that patients with low pretherapeutic Ang-2 serum levels
receiving a bevacizumab-containing treatment were associated with a better Response rate compared to patients with high pretherapeutic Ang-2 levels. Additionally to a reduced risk of death (>90%) patients with low pretherapeutic Ang-2 levels showed a
significant increase in progression-free survival (up to five months).

Further information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 10

Contact
Dipl.-Ing. Alfred Schillert

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.